Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Recruiting 3Unknown 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interventional × Endosonography × Clear all
NCT06831136 2025-09-10

PANCARDINAL-2

The University of Texas Health Science Center, Houston

Phase 2 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT06122896 2025-06-03

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Recruiting
5,000 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04990609 2025-05-21

EUS-RFA PANCARDINAL-1 Trial

The University of Texas Health Science Center, Houston

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡